Published in Nat Rev Drug Discov on December 01, 2003
Collection of Tissue Blocks or Slides From Patients With Cancer | NCT02810405
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol (2006) 2.17
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res (2010) 2.14
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab (2015) 1.89
Quantitative time-lapse fluorescence microscopy in single cells. Annu Rev Cell Dev Biol (2009) 1.32
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol (2006) 1.24
TAMEE: data management and analysis for tissue microarrays. BMC Bioinformatics (2007) 1.15
Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status. J Clin Pathol (2006) 1.05
Comparison of quantum dots immunofluorescence histochemistry and conventional immunohistochemistry for the detection of caveolin-1 and PCNA in the lung cancer tissue microarray. J Mol Histol (2009) 1.04
Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer (2012) 1.01
Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch (2010) 0.98
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One (2013) 0.97
High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One (2013) 0.97
Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer (2008) 0.96
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One (2014) 0.94
Transcriptional regulatory network refinement and quantification through kinetic modeling, gene expression microarray data and information theory. BMC Bioinformatics (2007) 0.93
Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. Br J Cancer (2009) 0.93
A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer (2007) 0.91
Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch (2007) 0.91
The detection of EBP50 expression using quantum dot immunohistochemistry in pancreatic cancer tissue and down-regulated EBP50 effect on PC-2 cells. J Mol Histol (2012) 0.89
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer (2016) 0.85
High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma. J Cancer Res Clin Oncol (2013) 0.84
Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray. Clin Cancer Res (2006) 0.81
BIRC2 amplification in squamous cell carcinomas of the uterine cervix. Virchows Arch (2012) 0.80
The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol (2012) 0.79
Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer (2010) 0.79
Recent developments in multiplexing techniques for immunohistochemistry. Expert Rev Mol Diagn (2015) 0.78
Vav3 oncogene is upregulated and a poor prognostic factor in breast cancer patients. Oncol Lett (2015) 0.77
Living Cell Microarrays: An Overview of Concepts. Microarrays (Basel) (2016) 0.77
High frequency of CD8 positive lymphocyte infiltration correlates with lack of lymph node involvement in early rectal cancer. Dis Markers (2014) 0.77
Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation. Sci Rep (2016) 0.76
The clinical impact of ICOS signal in colorectal cancer patients. Oncoimmunology (2016) 0.75
MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity. BMC Cancer (2016) 0.75
Downregulation of phosphorylated MKK4 is associated with a poor prognosis in colorectal cancer patients. Oncotarget (2017) 0.75
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol (2004) 3.49
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature (2004) 2.95
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest (2011) 2.60
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
Rhinosinusitis: Establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg (2004) 2.01
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch (2008) 1.61
Molecular cancer phenotype in normal prostate tissue. Eur Urol (2008) 1.58
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol (2006) 1.56
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Role of TP53 mutations in vulvar carcinomas. Int J Gynecol Pathol (2011) 1.47
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res (2013) 1.42
E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene (2004) 1.40
Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res (2007) 1.36
Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest (2004) 1.35
Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res (2009) 1.31
Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol (2005) 1.30
High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate (2010) 1.28
Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res (2010) 1.28
Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. J Thorac Oncol (2011) 1.26
The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res (2011) 1.26
TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer (2011) 1.26
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol (2006) 1.24
Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res (2005) 1.23
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol (2013) 1.22
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov (2012) 1.21
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res (2006) 1.17
HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol (2004) 1.15
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol (2010) 1.14
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res (2011) 1.13
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer (2012) 1.10
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch (2011) 1.10
Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer (2006) 1.07
Physiologic trauma triage criteria in adult trauma patients: are they effective in saving lives by transporting patients to trauma centers? J Am Coll Surg (2005) 1.07
Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res (2004) 1.06
SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate (2013) 1.06
Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol (2007) 1.04
Clinical practice guideline: endpoints of resuscitation. J Trauma (2004) 1.03
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One (2013) 1.02
Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol (2012) 1.02
Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol (2003) 1.02
Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol (2010) 1.01
Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. BMC Med Genet (2010) 1.01
Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer (2012) 1.00
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res (2008) 1.00
TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol (2004) 1.00
Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics (2009) 0.98
Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer (2010) 0.97
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin Cancer Res (2013) 0.97
Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome. Mod Pathol (2010) 0.95
Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. Int J Cancer (2014) 0.95
Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate (2009) 0.95
High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol (2003) 0.94
Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol (2002) 0.94
MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res (2011) 0.93
Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker. J Proteome Res (2010) 0.93
High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer (2012) 0.92
Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology (2010) 0.92
A community traffic safety analysis of pedestrian and bicyclist injuries based on the catchment area of a trauma center. J Trauma Acute Care Surg (2014) 0.92
Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. Hum Pathol (2009) 0.90
Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Exp Mol Pathol (2013) 0.90
Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. Endocrinology (2003) 0.90
Alcohol use by pedestrians who are struck by motor vehicles: how drinking influences behaviors, medical management, and outcomes. J Trauma (2011) 0.90
Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol (2012) 0.90
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol Oncol (2013) 0.89
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS (2012) 0.89
The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol Oncol (2007) 0.89
Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta (2006) 0.89
No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. PLoS One (2011) 0.89
Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. Cancer Res (2012) 0.89
Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma. J Oral Pathol Med (2013) 0.88
Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology (2010) 0.88
CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin Oral Investig (2013) 0.88
High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol (2005) 0.88
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases. Virchows Arch (2010) 0.87
Estrogen receptor gene amplification occurs rarely in ovarian cancer. Mod Pathol (2008) 0.87
Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol (2012) 0.86
High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int J Cancer (2005) 0.86
19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes Cancer (2010) 0.86
Predictive molecular pathology. N Engl J Med (2002) 0.85
Expression and amplification of therapeutic target genes in retinoblastoma. Graefes Arch Clin Exp Ophthalmol (2004) 0.85
The relationship between annual hospital volume of trauma patients and in-hospital mortality in New York State. J Trauma (2011) 0.85
Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer (2012) 0.85
Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. J Clin Pathol (2013) 0.84
Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch (2003) 0.84